Patents Assigned to Boehringer Ingelheim Pharma GmbH and Co. KG
  • 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition
    Publication number: 20050187227
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 and R2 are defined as in the claims, the tautomers, the stereoisomers, the mixtures thereof, and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: February 22, 2005
    Publication date: August 25, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Mohammad Tadayyon, Leo Thomas
  • Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
    Publication number: 20050182090
    Abstract: The invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one dopamine agonist or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
    Type: Application
    Filed: January 21, 2005
    Publication date: August 18, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Joachim Mierau, Michael Pieper
  • Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
    Publication number: 20050182043
    Abstract: The present invention relates methods for treating disease conditions selected from the list consisting of benign or malignant tumors, diseases of the airways and lungs, diseases of the gastrointestinal tract, the bile duct and the gall bladder by administration to a patient in need thereof of a therapeutically effective amount of a bicyclic heterocyclic groups of general formula wherein said substituents are as defined herein.
    Type: Application
    Filed: March 17, 2005
    Publication date: August 18, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Birgit Jung, Flavio Solca
  • Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist
    Publication number: 20050182089
    Abstract: Accordingly, the invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one NMDA receptor antagonists or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.
    Type: Application
    Filed: January 21, 2005
    Publication date: August 18, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Thomas Friedl, Joachim Mierau, Andreas Raschig, Juergen Reess
  • Pharmaceutical compositions containing anticholinergics and EGFR kinase inhibitors
    Publication number: 20050165013
    Abstract: The present invention relates to novel pharmaceutical compositions based on new anticholinergics and EGFR kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.
    Type: Application
    Filed: March 23, 2005
    Publication date: July 28, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Christopher Meade, Michel Pairet, Michael Pieper
  • Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors
    Publication number: 20050163726
    Abstract: The present invention relates to novel pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.
    Type: Application
    Filed: February 28, 2005
    Publication date: July 28, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Christopher Meade, Michel Pairet, Michael Pieper
  • Use of LTB4 antagonists in veterinary medicine
    Patent number: 6921752
    Abstract: The invention relates to the use of LTB4 antagonists for preparing a pharmaceutical composition for the treatment or prevention of respiratory diseases in companion and domesticated animals.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: July 26, 2005
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Franz Birke, Kandace Matzek
  • Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors
    Publication number: 20050159417
    Abstract: Disclosed are methods for a treating a disease or condition relating to blood coagulation and fibrinolysis using p38 MAP kinase inhibitors.
    Type: Application
    Filed: December 10, 2004
    Publication date: July 21, 2005
    Applicants: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Chester Wood, Tom van der Poll
  • Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
    Publication number: 20050159436
    Abstract: The present invention relates to bicyclic heterocycles of general formula wherein Ra, Rb, Rc, A, B, C, D, E and X are defined as in claim 1, the tautomers, the stereoisomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for treating diseases, particularly tumoral diseases, as well as benign prostatic hyperplasia (BPH), diseases of the lungs and respiratory tract, and the preparation thereof.
    Type: Application
    Filed: March 15, 2005
    Publication date: July 21, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Birgit Jung, Flavio Solca
  • Pharmaceutical compositions based on anticholinergics and additional active ingredients
    Publication number: 20050148562
    Abstract: A pharmaceutical composition comprising an anticholinergic and at least one additional active ingredient selected from among corticosteroids, dopamine agonistes, PDE-IV inhibitors, NK1-antagonists, endothelin antagonists, antihistamines, and EGFR-kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.
    Type: Application
    Filed: December 8, 2004
    Publication date: July 7, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. Kg
    Inventors: Michel Pairet, Michael Pieper, Christopher Meade, Richard Reichl, Christel Schmelzer, Birgit Jung
  • Betamimetics having a long-lasting activity, processes for preparing them, and their use as medicaments
    Publication number: 20050137242
    Abstract: A compound of formula 1 wherein: R1 is a group wherein R3 is a benzyl group optionally substituted by a methoxy group; R4 is a hydrogen atom, or R3 and R4 together are a —CO—CH2—O— bridge, the carbonyl group of the bridge being bound to the nitrogen; and R2 is a group selected from wherein R5 is a dimethylamino, methoxy, or butoxy group, X is a nitrogen or a carbon atom, and R6 is a methoxyphenyl group, if X is nitrogen, or is an anellated phenyl ring also linked to X, if X is carbon, or the individual optical isomers, mixtures of the individual enantiomers, racemates, or acid addition salt thereof.
    Type: Application
    Filed: February 8, 2005
    Publication date: June 23, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Alexander Walland, Kurt Schromm, Karl-Heinz Bozung, Herman Schollenberger
  • Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide
    Publication number: 20050137233
    Abstract: The present invention relates to new compounds of general formula having thrombin-inhibiting activity. Exemplary are: 1-Methyl-2-[4-(N-hydroxyamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-ethoxycarbonylethyl)-amide, and 1-Methyl-2-[4-(N-methoxycarbonylamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide.
    Type: Application
    Filed: February 11, 2005
    Publication date: June 23, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Norbert Hauel, Florian Colbatzky, Ulrich Busch
  • Industrial process for preparing tropenol
    Publication number: 20050124813
    Abstract: The invention relates to a new industrially useable process for preparing tropenol, optionally in the form of the acid addition salts thereof.
    Type: Application
    Filed: January 18, 2005
    Publication date: June 9, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Gisela Bodenbach, Andreas Mathes, Helmut Meissner, Peter Specht
  • Pyrimidine derivatives useful as inhibitors of PKC-theta
    Publication number: 20050124640
    Abstract: Disclosed are novel compounds of formula (I): wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: September 3, 2004
    Publication date: June 9, 2005
    Applicants: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Mario Cardozo, Derek Cogan, Charles Cywin, George Dahmann, Darren DiSalvo, John Ginn, Anthony Prokopowicz, Denice Spero, Erick Young
  • Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide
    Patent number: 6900229
    Abstract: The present invention relates to new compounds of general formula having thrombin-inhibiting activity. Exemplary are: 1-Methyl-2-[4-(N-hydroxyamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-ethoxycarbonylethyl)-amide, and 1-Methyl-2-[4-(N-methoxycarbonylamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide.
    Type: Grant
    Filed: July 31, 2003
    Date of Patent: May 31, 2005
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Norbert Hauel, Florian Colbatzky, Ulrich Busch
  • Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
    Patent number: 6900317
    Abstract: The invention relates to salts of the active substance base 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine [BIBN4096] of formula I, the preparation thereof, a process for preparing an inhalation powder containing a salt of the active substance BIBN4096 as well as the inhalation powders which can be obtained by the process.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: May 31, 2005
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Michael Trunk, Claudius Weiler
  • Process for the manufacture of 4-(6-bromohexyloxy)-butylbenzene
    Publication number: 20050113608
    Abstract: The present invention relates to an improved process for preparing 4-(6-bromohexyloxy)-butylbenzene by reacting 4-phenylbutanol with 1,6-dibromohexane in the presence of a base and a phase transfer catalyst, wherein 4-phenylbutanol in a diluent is metered into a mixture consisting of 1,6-dibromohexane, a base, a phase transfer catalyst and a diluent, and the use of the 4-(6-bromohexyloxy)-butylbenzene thus prepared for producing salmeterol in a method known per se.
    Type: Application
    Filed: October 29, 2004
    Publication date: May 26, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Oliver Meyer, Helmut Heitger
  • Neomycin-phosphotransferase-genes and methods for the selection for recombinant cells producing high levels of a desired gene product
    Publication number: 20050106580
    Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.
    Type: Application
    Filed: November 26, 2003
    Publication date: May 19, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Barbara Enenkel, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
  • Industrial process for preparing tropenol
    Patent number: 6891042
    Abstract: The invention relates to a new industrially useable process for preparing tropenol, optionally in the form of the acid addition salts thereof.
    Type: Grant
    Filed: January 26, 2004
    Date of Patent: May 10, 2005
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rolf Banholzer, Gisela Bodenbach, Andreas Mathes, Helmut Meissner, Peter Specht
  • Administration form for the oral application of poorly soluble drugs
    Publication number: 20050095293
    Abstract: The invention relates to a new formulation for oral administration of active substances with pH-dependent solubility characteristics and the pharmacologically acceptable salts thereof, which improves the bioavailability of the active substance.
    Type: Application
    Filed: September 3, 2004
    Publication date: May 5, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH Co. KG
    Inventors: Ulrich Brauns, Rolf-Stefan Brickl